Mesothelioma Treatment Options in 2026: What Patients Need to Know

Treating Mesothelioma in 2026: A Rapidly Evolving Landscape

Mesothelioma treatment has advanced significantly in the past decade, driven by the 2020 FDA approval of immunotherapy as a first-line option and continued progress in surgical techniques for selected patients. While mesothelioma remains a difficult cancer to treat, today's patients have more therapeutic options than any previous generation — and research is advancing rapidly.

Treatment decisions for mesothelioma require a multidisciplinary team with specific expertise in asbestos-related cancers. Mayo Clinic's Mesothelioma Specialty Group, for example, brings together thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, and palliative care specialists to develop individualized treatment plans.^[7] Seeking care at a center with this level of mesothelioma expertise can meaningfully affect outcomes.

The NCI Treatment PDQ for mesothelioma outlines the major evidence-based treatment modalities currently in use.^[4]

Immunotherapy: The 2020 FDA Breakthrough

The most significant recent development in mesothelioma treatment was the FDA's October 2, 2020 approval of nivolumab (Opdivo) plus ipilimumab (Yervoy) as first-line treatment for adults with unresectable malignant pleural mesothelioma. This was the first new drug approval for mesothelioma in 16 years.^[1]

The approval was based on results from the CheckMate-743 trial, published in The Lancet. The trial showed median overall survival of 18.1 months with nivolumab + ipilimumab versus 14.1 months with platinum-based chemotherapy — a statistically significant improvement. Crucially, the benefit was most pronounced in patients with non-epithelioid (sarcomatoid and biphasic) tumors, a group that historically had very poor outcomes with chemotherapy.^[2]

Both nivolumab and ipilimumab are immune checkpoint inhibitors — they work by blocking proteins (PD-1 and CTLA-4, respectively) that prevent the immune system from attacking cancer cells. Their combination produces a synergistic anti-tumor effect. Side effects can include immune-related adverse events affecting the lungs, liver, colon, and endocrine glands, and require prompt management by experienced oncologists.

Chemotherapy: The Established Standard

Before immunotherapy, platinum-based chemotherapy was the only FDA-approved systemic treatment for mesothelioma. The standard regimen — pemetrexed (Alimta) plus cisplatin — was approved by the FDA on February 4, 2004 based on a Phase III trial showing median overall survival of 12.1 months versus 9.3 months for cisplatin alone.^[3][5]

Pemetrexed plus carboplatin (a less toxic alternative to cisplatin) is also used in patients who cannot tolerate cisplatin. In 2024, the FDA also approved pemetrexed in combination with platinum chemotherapy and pembrolizumab (Keytruda) for certain patients, expanding the immunotherapy-chemotherapy combination options.

Chemotherapy remains a common treatment choice, particularly for patients who are not candidates for surgery or for whom immunotherapy is contraindicated. It may also be used in combination with surgery (as adjuvant therapy after surgery or in the HIPEC protocol for peritoneal mesothelioma) or radiation.

Surgical Options for Mesothelioma

Surgery plays a role in treatment for carefully selected patients with early-stage mesothelioma. For pleural mesothelioma, two main surgical procedures exist:^[6]

• Pleurectomy/Decortication (P/D): Removes the pleura (lining around the lungs) but preserves the lung itself. Less radical than EPP; associated with lower operative mortality and increasingly preferred by surgeons when achievable.
• Extrapleural Pneumonectomy (EPP): Removes the affected lung, the pleura, part of the diaphragm, and the pericardium. More extensive surgery reserved for fit patients with localized, epithelioid tumors at experienced centers.

For peritoneal mesothelioma, cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC) has produced dramatic improvements in survival for eligible patients. Published outcomes report median survival exceeding 50 months in carefully selected peritoneal mesothelioma patients — substantially better than chemotherapy alone.^[10]

Surgical candidacy depends on stage, cell type, age, lung function, and overall health. Patients considering surgery should seek evaluation at centers performing high volumes of mesothelioma operations, as outcome data consistently demonstrates better results at experienced institutions.

Radiation Therapy

Radiation therapy is not typically curative for mesothelioma but plays an important role in multimodal treatment plans and in controlling local symptoms. Mayo Clinic notes that radiation may be used:^[6]

• After surgery to kill remaining cancer cells (adjuvant radiation)
• To reduce the size of a tumor before surgery (neoadjuvant radiation)
• For palliation — relieving pain, shortness of breath, or other symptoms caused by tumor growth
• To prevent tumor seeding in biopsy or surgical tracts (prophylactic radiation)

Intensity-modulated radiation therapy (IMRT) and proton beam therapy allow more precise targeting that spares healthy tissue, and are increasingly used in mesothelioma treatment at specialty centers.

Clinical Trials and Emerging Therapies

The American Cancer Society and NCI highlight several emerging treatment approaches currently in clinical trials:^[11][9]

• CAR T-cell therapy: NCI's Center for Cancer Research is conducting a Phase I trial targeting mesothelin — a protein overexpressed on mesothelioma cells — with CAR T cells. The NIH Clinical Center provides medical care at no cost to participants.^[8]
• Additional checkpoint inhibitors: Multiple trials are evaluating combinations of PD-1, PD-L1, and CTLA-4 inhibitors beyond the approved nivolumab + ipilimumab regimen
• Tumor treating fields (TTFields): A non-invasive device (Optune Lua) delivering alternating electric fields has shown preliminary benefit in mesothelioma and received FDA approval for use with pemetrexed chemotherapy in 2019
• Targeted therapies: BAP1 mutation, NF2 loss, and other molecular alterations in mesothelioma are being studied as potential targets for precision medicine approaches
• Combination immunotherapy + chemotherapy: Multiple trials are evaluating the addition of checkpoint inhibitors to standard chemotherapy regimens in hopes of further improving outcomes

Patients and families can search for open clinical trials at ClinicalTrials.gov or through the NCI's mesothelioma clinical trials finder. Participation in a clinical trial is often the best way to access the most current therapeutic options — and contributes to research that benefits future patients.

Frequently Asked Questions